Fecal microbiota transplantation is an efficacious and inexpensive therapy for recurrent Clostridium difficile infection, yet its safety is thought to depend on appropriate fecal donor screening. FDA guidance for regulation of this procedure is in flux, but screening and manufacture of fecal material from asymptomatic donors present many challenges to clinical laboratories. This minireview summarizes FDA regulatory changes, principles of donor selection, and recommended laboratory screening practices for fecal microbiota transplantation.
CITATION STYLE
Woodworth, M. H., Neish, E. M., Miller, N. S., Dhere, T., Burd, E. M., Carpentieri, C., … Kraft, C. S. (2017). Laboratory testing of donors and stool samples for fecal microbiota transplantation for recurrent clostridium difficile infection. Journal of Clinical Microbiology, 55(4), 1002–1010. https://doi.org/10.1128/JCM.02327-16
Mendeley helps you to discover research relevant for your work.